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Objectives: Accelerated approval pathways can shorten time to market for thera-
pies treating diseases, particularly those with significant morbidity and mortality 
and few effective alternatives. However, little is known about payers’ reactions to 
submissions based on a Phase 2, single-arm trial. This study aimed to identify mar-
ket access challenges for products with accelerated marketing authorization based 
on this limited data package. MethOds: Oncology products receiving European 
marketing authorization since 2012 based on a Phase 2, single-arm study were 
identified and the associated EPARs and HTA submissions in France, Germany and 
the UK (NICE) reviewed. Results: Six products were identified (Adcetris, Bosulif, 
Erivedge, Iclusig, Imbruvica, and Zydelig); four had orphan designation. No pivotal 
trials included survival as the primary endpoint, none reported HRQL and no com-
parative data were cited in the regulatory packages. Only one product was reviewed 
by NICE (England) and was not recommended (another did not submit). All six G-BA 
(Germany) reviews resulted in either additional benefit not proven, not quantifiable 
(or minor in one subgroup). In France, the ASMR ratings ranged from III to V (mod-
erate, to no improvement compared with existing treatments). Common themes 
identified which could be addressed by additional evidence generation included: (1) 
clarity on the target patient population and unmet need; (2) establishing the cur-
rent standard of care and positioning within the treatment pathway; (3) determin-
ing relative efficacy given the focus on survival benefit and the increasing weight 
of additional value drivers. cOnclusiOns: Although marketing authorization is 
granted, products supported by Phase 2, single-arm trial data face significant HTA 
challenges; payers are being asked to make decisions based on limited data. Some 
evidence gaps can be addressed with additional evidence generated alongside the 
pivotal trial. However, uncertainty about a product’s value may result in poor HTA 
outcomes, and a poor position from which to negotiate price.
PCN323
Does BuDget ImPaCt affeCt ReImBuRsemeNt DeCIsIoNs maDe By the 
CaNCeR DRugs fuND IN eNglaND?
Stewart G, Kusel J, Montgomery S
Costello Medical Consulting Ltd, Cambridge, UK
Objectives: The Cancer Drugs Fund (CDF) in England has an annual budget of 
£280 million to fund cancer drugs on the NHS that were not assessed by or were 
rejected by NICE. In 2014, drugs on the CDF were re-assessed based on criteria 
including cost per patient and 16 were removed from the list. Previous analy-
sis on a sub-set of the drugs that were re-assessed indicated that drugs with a 
higher budget impact might be more likely to be rejected by the CDF (presented 
at HTAi 2015). We aimed to expand the analysis to all those re-appraised by 
the CDF, to investigate whether this trends holds when a larger sample size is 
used. MethOds: Using the cost per cycle, cycle length and median duration of 
treatment extracted from the CDF decision summaries, the cost per patient was 
calculated for every drug assessed in 2014. The budget impact of those drugs that 
had previously been reimbursed by the CDF was calculated based on the number of 
notifications that the CDF received in 2014. A point-biserial correlation coefficient 
(rpb) was used to assess whether cost per patient and total budget impact were 
correlated with the CDF reimbursement decision. Results: Investigation of the 
larger sample set confirmed the initial results of the previous analysis and deter-
mined that there was a positive correlation for cancer drugs with a higher cost per 
patient to be included in the CDF (rpb= 0.643); this is most likely due to the superior 
clinical evidence. The budget impact was found to have little influence on the CDF 
reimbursement decision in this larger sample size (rpb= 0.105). cOnclusiOns: 
Although the CDF’s new criteria for reimbursement do involve an evaluation of 
the cost of each drug, it seems that neither the cost per patient nor the overall 
budget impact greatly influences their decisions.
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Objectives: To assess the impact of PRO data collected after clinical progression 
(i.e., postprogression) on payer decision making in oncology. MethOds: One-on-
one interviews were conducted with 16 payers and payer advisors from 14 countries 
in 2014. An online assessment was conducted (December 8, 2014, to March 4, 2015) 
with 20 completed surveys (China, France, Germany, Spain, Taiwan, the UK, the US) 
and 7 partially completed surveys (Australia, South Korea, the US) by payers from 
the RTI Health Solutions Global Payer Advisory Panel. Results: PRO data are com-
monly collected during trials; however, collection of PRO data postprogression is 
less common. When asked about the value of collecting PRO data postprogression, 
payers indicated that they consider this particularly important in cancer types with 
relatively long survival and those that involve palliative and/or long-term care. All 
payers in the one-on-one interviews advised collecting postprogression PRO data in 
both the control and comparator arms. Eleven of the 16 respondents in the one-on-
one interviews indicated that it is worthwhile to collect PRO data postprogression 
and that positive PRO data may support continued therapy, even if the tumor is pro-
gressing. Results from the online assessment indicated that payers outside the US 
considered postprogression PRO data more useful than US payers did. When queried 
about specific types of postprogression data, payers generally thought that all types 
of PRO data examined (stability of disease, improvement in health-related quality 
of life, improvement in symptom severity or frequency, improvement in functional 
status, slower rate of functional deterioration compared to control/comparator arm) 
were important to decision making. Payers generally deferred to clinical experts on 
the length and frequency of postprogression PRO data collection. cOnclusiOns: 
PRO data provide compelling evidence even after tumors have progressed clinically 
and may help differentiate products, especially in situations where therapies do not 
provide significant survival benefits.
time gap from TFDA approval to reimbursement on mortality for advanced CRC 
patients. MethOds: The data was form 2 million sampling reimbursement data 
set of Taiwan’s National Health Insurance Research Database (NHIRD) and diseased 
stage was derived from the Taiwan Cancer Registry (TCR) between 2007 and 2011. 
Diseased stage diagnosed for the first time ever of CRC patients was recorded in TCR. 
Patients’ survival data and prescription time of target therapy were derived. Fisher 
exact test was used for the comparisons of frequencies; log rank was used survival 
comparisons; and hazard ratio was derived using both Cox regression with time 
and time independent analysis. Results: 364 staged 4 CRC patients were derived 
and enrolled into the analysis. There were 11 patients diagnosed with CRC before 
the target therapy was approved for reimbursement, whereas 353 were diagnosed 
after. 70 of them were prescribed target therapy during the disease treatment period. 
Median survival years for those who were prescribed target therapy was 2.6 as com-
pared to 1.2 without. There was a statistical significant survival difference between 
target therapy use after the reimbursement approval and non target therapy use 
before approval, HR = 0.073(0.031-0.176), p < 0.0001. The use of target therapy and 
non user was also significant with HR = 0.53(0.369-0.759), p = 0.0005. Multivariate 
Cox regression suggested that the effect of time gap in target therapy reimburse-
ment approval was statistical significant with p = 0.0019 cOnclusiOns: Time gap 
due to reimbursement process influences patient’s mortality. Shortening the time 
gap to reimbursement approval is suggested.
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Objectives: 135 dossiers have been evaluated by G-BA since AMNOG was intro-
duced. Looking at oncology products, 43 have started into AMNOG process and for 
38 G-BA has finalized its decision. In 32 assessments an additional benefit was 
granted, leading to a success rate of 84% compared to only 36% in non-oncology 
products. Objective of this research is to identify drivers responsible for successful 
benefit assessment outcomes in oncology. MethOds: All oncology assessments 
were analysed to reveal key drivers responsible for positive assessments by IQWiG 
+ G-BA. Next to comparator choice the analysis focused on submitted endpoints, 
where it is evaluated which endpoints contribute most in oncology indications 
to additional benefit. Results: Additional benefit is assessed based on patient 
relevant endpoints (mortality, morbidity, quality of life & safety). More than 55% 
of submitted endpoints fall in the safety category, followed by morbidity (approx. 
30%), mortality (approx. 10%) and quality of life (approx. 5%). OS has shown to be 
the most relevant endpoint, where the G-BA granted additional benefit in 23 out of 
32 dossiers primarily based on OS data. In terms of morbidity, PFS, ORR and “Time 
to Pain Progression” are the top three submitted morbidity endpoints; however, only 
“Time to Pain Progression” led to additional benefit in 2 out of 3 cases and QoL led 
to additional benefit in 4 cases. cOnclusiOns: OS will continue to be the most 
relevant endpoint for IQWiG + G-BA when determining the additional benefit in 
oncology. In the absence of OS, PFS will not help in the overall additional benefit 
decision by G-BA, unless the MNF can justify PFS to be patient relevant according 
to IQWiG methodology. Although QoL is an accepted endpoint by G-BA, due to the 
high methodological standards set by G-BA and IQWiG chances are low that a QoL 
improvement alone will lead to additional benefit.
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Objectives: Many oncological drugs that are being used in the adjuvant setting 
were first submitted for reimbursement in the metastatic stage, with differences 
in incremental cost-effectiveness ratios (ICERs) in both settings having potential 
implications for reimbursement and pricing. The aim of this study is to identify 
a possible trend in the cost-effectiveness for the early/adjuvant and late/meta-
static stages of oncological drugs through review and case study. MethOds: We 
reviewed pairs of cost-effectiveness analyses of the same oncological drug in 
different stages for Scotland and the Netherlands. The case study in this report 
was directed at trastuzumab in the Dutch situation. Using a simplified Markov 
model, the cost-effectiveness in early and late stage of breast cancer was cal-
culated and compared to the findings from the review. Results: Comparable 
studies were found for cetuximab, bortezomib and bosutinib. Treatments in the 
late stage were found to be more expensive per QALY by a factor ranging from 
1.5 to 12. The case study provided a similar result; late stage treatment was more 
expensive by a factor 10. Using, for example, a threshold of € 80,000/QALY, the early 
stage of cetuximab, bosutinib and trastuzumab are deemed cost-effective, while 
their compared late stage is lifted over the threshold and potentially considered 
not cost-effective. cOnclusiOns: ICERs of oncological drugs used in different 
stages are more unfavourable in the late stage than in the early stage. Applying 
a reasonable threshold may result in early stage treatment being deemed cost-
effective while late stage potentially not. Authorities should be aware of this when 
assessing oncological drugs and interpreting the corresponding ICERs, in the situ-
ation where oncological drugs are generally most submitted for reimbursement 
in the late stage initially.
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